OverviewChartNewsTraderScreen

BNP Paribas Bonus Zert SNW 27.06..../  DE000PE5QQZ4  /

EUWAX
14/06/2024  09:52:17 Chg.+0.02 Bid22:00:36 Ask22:00:36 Underlying Strike price Expiration date Option type
79.93EUR +0.03% -
Bid Size: -		 -
Ask Size: -		 SANOFI SA INHABER ... - - 27/06/2024 Call
GlobeNewswire 12:10 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 03/06 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 31/05 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31/05 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 31/05 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 30/05 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 27/05 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 23/05 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 21/05 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 20/05 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 20/05 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 13/05 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 13/05 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 10/05 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 10/05 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 10/05 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 09/05 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 09/05 Europe opens mixed with BoE in focus
GlobeNewswire 08/05 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 07/05 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights